# A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

> **NCT01652547** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Metastatic Melanoma and Merkel Cell Carcinoma

## Interventions

- **DRUG:** Pasireotide sub-cutaneous formulation
- **DRUG:** Pasireotide lon acting release formulation

## Key facts

- **NCT ID:** NCT01652547
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01652547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01652547, "A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01652547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*